HuGE Literature Finder
Records
1
-
13
| Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Scientific reports 2022 Jun 12 (1): 9559. Huang Fuxue, Li Jingjing, Wen Xizhi, Zhu Baoyan, Liu Wei, Wang Jiuhong, Jiang Hang, Ding Ya, Li Dandan, Zhang Xiaos |
| Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation. The oncologist 2022 May . Huang Richard S P, Tse Julie Y, Harries Lukas, Graf Ryon P, Lin Douglas I, Murugesan Karthikeyan, Hiemenz Matthew C, Parimi Vamsi, Janovitz Tyler, Decker Brennan, Severson Eric, Levy Mia A, Ramkissoon Shakti H, Elvin Julia A, Ross Jeffrey S, Williams Erik |
| Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatric dermatology 2022 Feb . Church Alanna J, Moustafa Danna, Pinches Robert Seth, Hawryluk Elena B, Schmidt Birgitta A |
| Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. Melanoma research 2022 10 32 (5): 373-378. Lasocki Arian, McArthur Grant |
| NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. Frontiers in immunology 2022 13 894110. Li Hongxia, Zhang Qin, Duan Qianqian, Tan Yuan, Sun Tingting, Qi Chua |
| PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers 2021 Sep 13 (18): . Cho Yoon Ah, Lee Hyunwoo, Kim Deok Geun, Kim Hyunjin, Ha Sang Yun, Choi Yoon-La, Jang Kee-Taek, Kim Kyoung-M |
| Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database. Cancer reports (Hoboken, N.J.) 2021 Jun e1380. Dimitrova Maya, Kim Min Jae, Osman Iman, Jour Geor |
| No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers 2021 Jan 13 (3): . Guida Michele, Bartolomeo Nicola, Quaglino Pietro, Madonna Gabriele, Pigozzo Jacopo, Di Giacomo Anna M, Minisini Alessandro M, Tucci Marco, Spagnolo Francesco, Occelli Marcella, Ridolfi Laura, Queirolo Paola, De Risi Ivana, Quaresmini Davide, Gambale Elisabetta, Chiaron Sileni Vanna, Ascierto Paolo A, Stigliano Lucia, Strippoli Sabino, On Behalf Of The Italian Melanoma Intergroup Imi Stud |
| Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific reports 2020 Oct 10 (1): 17687. Aoude Lauren G, Bonazzi Vanessa F, Brosda Sandra, Patel Kalpana, Koufariotis Lambros T, Oey Harald, Nones Katia, Wood Scott, Pearson John V, Lonie James M, Arneil Melissa, Atkinson Victoria, Smithers B Mark, Waddell Nicola, Barbour Andrew |
| CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. Journal of the American Academy of Dermatology 2018 Sep . Dalmasso Bruna, Pastorino Lorenza, Ciccarese Giulia, Andreotti Virginia, Grillo Federica, Mastracci Luca, Spagnolo Francesco, Ballestrero Alberto, Queirolo Paola, Bruno William, Ghiorzo Pao |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of gastrointestinal oncology 2018 Aug 9 (4): 610-617. Fabrizio David A, George Thomas J, Dunne Richard F, Frampton Garrett, Sun James, Gowen Kyle, Kennedy Mark, Greenbowe Joel, Schrock Alexa B, Hezel Aram F, Ross Jeffrey S, Stephens Phillip J, Ali Siraj M, Miller Vincent A, Fakih Marwan, Klempner Samuel |
| Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute 2016 Nov 108 (11): . Helgadottir Hildur, Höiom Veronica, Tuominen Rainer, Nielsen Kari, Jönsson Göran, Olsson Håkan, Hansson Joh |
| BRAF mutations in advanced cancers: clinical characteristics and outcomes. PloS one 2011 6 (10): e25806. El-Osta Hazem, Falchook Gerald, Tsimberidou Apostolia, Hong David, Naing Aung, Kim Kevin, Wen Sijin, Janku Filip, Kurzrock Razel |
- Page last reviewed:Jul 25, 2022
- Page last updated:Nov 30, 2022
- Content source: